The content on this site is intended for healthcare professionals only
Prof Bradley Monk talks to ecancer for the ESMO 2021 meeting about the results from the phase III KEYNOTE-826 study which looked at the addition of pembrolizumab to chemotherapy for recurrent, persistent or metastatic cervical cancer.
He explains that this was a randomised, double-blind study of 617 patients where the addition of pembrolizumab was compared to placebo on top of carboplatin/cisplatin and paclitaxel.
Prof Monk reports that the study met primary endpoints of overall survival and progression free survival with a 33% improvement in patients that were alive at 2 years in the all-comers subgroup.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ASCO 2024: Lung cancer highlights
ASCO 2024: Lung cancer roundup
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer
Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
OncoAlert round up July 28th to August 3rd, 2023
